Previous close | 1.4680 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 21,015 |
Market cap | 270,383 |
Beta (5Y monthly) | 2.73 |
PE ratio (TTM) | N/A |
EPS (TTM) | -7.8050 |
Earnings date | 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.
Immunovia AB (publ) today announced that the Annual Report for 2023 has been published.
Immunovia Publishes Interim Report for January-March 2024